We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Ligand Pharmaceuticals Incorporated | NASDAQ:LGND | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.39 | 0.54% | 73.22 | 72.00 | 76.00 | 75.615 | 73.155 | 73.50 | 162,711 | 00:17:20 |
From Nov 2023 to May 2024
By Ben Glickman
Ligand Pharmaceuticals said its treatment for molluscum, a viral skin infection, had received approval from U.S. regulators.
The company said Friday that the U.S. Food and Drug Administration had approved Zelsuvmi, a topical prescription medication, to treat moluscum in adults and children one year old or older.
Ligand expects the treatment to be available in the U.S. in the second half of 2024.
The company said the FDA had approved Zelsuvmi as the first novel drug to treat mollescum infections.
Molluscum is a contagious skin infection which can cause lesions. It primarily affects children.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 05, 2024 17:25 ET (22:25 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Ligand Pharmaceuticals Chart |
1 Month Ligand Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
